Adults 40 to 80, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
NFC Blood Flow at Baseline and 15 MinutesPrimary· baseline and 15 minutes
NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.
Baseline
Group
Value
95% CI
Latanoprost 0.005%
72.52
± 37.76
Latanoprost Bunod 0.024%
83.94
± 78.31
Normal Saline 0.9%
93.01
± 61.4
15 minutes
Group
Value
95% CI
Latanoprost 0.005%
60.50
± 42.81
Latanoprost Bunod 0.024%
75.57
± 44.68
Normal Saline 0.9%
69.70
± 41.46
Sponsor's own description
The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT04630808 — MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
· Phase 3
· completed
NCT03657797 — Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Gla
· Phase 2
· completed
NCT03293992 — A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillatio
· Phase 1
· completed
NCT00572455 — Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
· Phase 2
· completed
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
· Phase 2
· recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma
· NA
· recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
· Phase 3
· recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
· Phase 3
· recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma
· NA
· active not recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
NCT07094308 — The LIFT-ECHO Last Mile Project
· NA
· not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils
· not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction
· NA
· not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
· NA
· not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and
· Phase 2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03949244.